Amgen Foundation commits $2.5 million in new grants to engage 50,000 students each year in the thrill of scientific inquiry

AmgenThe Amgen Foundation has announced $2.5 million in new grants for the Amgen Biotech Experience, an innovative science education program, bringing the total committed to nearly $8 million since the program's inception in 1990. The Amgen Biotech Experience provides a real-world biotech lab experience to middle and high schools in Amgen's U.S. and United Kingdom (U.K.) communities and will engage more than 50,000 students this year. Education Development Center, Inc. (EDC), a global nonprofit organization that creates learning opportunities around the world, has also been named Program Office to oversee the program's implementation and facilitate its continued development.

Cutbacks in educational funding have led to limited resources for hands-on scientific experiences in many communities, and the National Academies' National Research Council has shown a significant connection between strong lab experiences and teachers' abilities to generate student interest in science. The Amgen Biotech Experience seeks to help make this connection in secondary school classrooms by introducing students to contemporary science techniques, including a robust, hands-on curriculum, research-grade equipment and comprehensive teacher training.

"By providing cutting-edge scientific experience today, students can begin to develop capabilities to make a powerful impact on society tomorrow," said Robert A. Bradway, chairman and chief executive officer of Amgen. "The Amgen Biotech Experience, designed in collaboration with educators and Amgen scientists, provides a rigorous real-world experience that helps open students' eyes to the world of biotechnology and scientific discovery."

In 2013, the Amgen Foundation will give more than $2.5 million in grants to community colleges, universities and nonprofit organizations that lead and support the Amgen Biotech Experience in different regions across the country where Amgen has a presence, including Southern and Northern California, Colorado, Washington, Rhode Island, Massachusetts, Puerto Rico and the U.K. The program will also be introduced in Washington, D.C., in 2014.

Since 1990, the Amgen Biotech Experience has engaged more than 300,000 students in learning molecular biology using relevant curricula, tools and techniques. Teachers are given a hands-on, inquiry-based, biology curriculum, in addition to a full suite of transportable, research-grade equipment and supplies, at no cost to the participating schools. Utilizing Nobel Prize-winning discoveries to prepare a recombinant DNA molecule that carries a gene for red fluorescent protein, students follow many of the steps biotechnology researchers use to produce medicines.

"I have been using the Amgen Biotech Experience in my classroom since 2008, and it is inspiring to see how eager the students are to learn these lab techniques. Several students have even told me they want to pursue a major in biology after they finish the course," said Amy Welch, a biology teacher at Brea Olinda High School in Brea, Calif. "As a teacher, my knowledge of biotechnology lab techniques has increased immensely since I first implemented the program and I feel that I am providing my students with skills that make them strong scientific thinkers. Given its genuine impact, I am so thankful to the Amgen Foundation for making this program possible."

Beginning this year, EDC will apply its deep experience in designing and delivering high-quality science education programs to establishing a Program Office for the Amgen Biotech Experience. Working closely with existing sites, EDC will build on the assets of the program and implement strategies to enrich the program, including the introduction of a new strengthened curriculum for this school year.

"EDC has a 50-year history of sharing the excitement of science learning with teachers and students," said Luther Luedtke, president and chief executive officer of EDC. "We are pleased to work alongside the Amgen Foundation to continue to make science compelling in the classroom and to encourage students to take up science-related careers."

For more information, please visit www.amgenbiotechexperience.com.

The Amgen Foundation supports numerous national and international organizations that strive to strengthen STEM (science, technology, engineering, mathematics) education and inspire students to pursue careers in science. To date, the Amgen Foundation has committed more than $80 million in science education funding to nonprofit organizations throughout the U.S., Puerto Rico and Europe.

About Amgen Foundation
The Amgen Foundation seeks to advance science education, improve patient access to quality care, and strengthen the communities where Amgen staff members live and work. To date, the Foundation has donated more than $200 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally.

About EDC
Education Development Center, Inc. (EDC) is a global nonprofit organization with headquarters located outside Boston, Massachusetts. EDC's mission is to create learning opportunities for people around the world, empowering them to pursue healthier and more productive lives. EDC works with public-sector and private partners, harnessing the power of people and systems to improve education, health promotion and care, workforce preparation, communications technologies and civic engagement. EDC manages 250 projects in 30 countries.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...